Chinese General Practice ›› 2020, Vol. 23 ›› Issue (5): 511-515.DOI: 10.12114/j.issn.1007-9572.2019.00.266
Special Issue: 泌尿系统疾病最新文章合集
• Monographic Research • Previous Articles Next Articles
Published:
2020-02-15
Online:
2020-02-15
[1]ZHANG L X,WANG F,WANG L,et al.Prevalence of chronic kidney disease in China:a cross-sectional survey[J].Lancet,2012,379(9818):815-822.DOI:10.1016/s0140-6736(12)60033-6. [2]FORNI OGNA V,OGNA A,PONTE B,et al.Prevalence and determinants of chronic kidney disease in the Swiss population[J].Swiss Med Wkly,2016,146:w14313.DOI:10.4414/smw.2016.14313. [3]LIYANAGE T,NINOMIYA T,PERKOVIC V,et al.Chronic kidney disease in Asia:protocol for a collaborative overview[J].Nephrology (Carlton),2017,22(6):456-462.DOI:10.1111/nep.12821. [4]NG J K,LI P K.Chronic kidney disease epidemic:How do we deal with it?[J].Nephrology(Carlton),2018,23(Suppl 4):116-120.DOI:10.1111/nep.13464. [5]LIU M,LI X C,LU L,et al.Cardiovascular disease and its relationship with chronic kidney disease[J].Eur Rev Med Pharmacol Sci,2014,18(19):2918-2926. [6]KURIYAMA S,MARUYAMA Y,NISHIO S,et al.Serum uric acid and the incidence of CKD and hypertension[J].Clin Exp Nephrol,2015,19(6):1127-1134.DOI:10.1007/s10157-015-1120-4. [7]CHRISTENSSON T.Serum urate in subjects with hypercalcaemic hyperparathyroidism[J].Clin Chim Acta,1977,80(3):529-533. [8]BERGENFELZ A,BLADSTR?M A,THEIR M,et al.Serum levels of uric acid and diabetes mellitus influence survival after surgery for primary hyperparathyroidism:a prospective cohort study[J].World J Surg,2007,31(7):1393-1402.DOI:10.1007/s00268-007-9091-6. [9]CHEN W,RONCAL-JIMENEZ C,LANASPA M,et al.Uric acid suppresses 1 alpha hydroxylase in vitro and in vivo[J].Metab Clin Exp,2014,63(1):150-160.DOI:10.1016/j.metabol.2013.09.018. [10]NEER R M,ARNAUD C D,ZANCHETTA J R,et al.Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis[J].N Engl J Med,2001,344(19):1434-1441.DOI:10.1056/NEJM200105103441904. [11]SUGIMOTO R,WATANABE H,IKEGAMI K,et al.Down-regulation of ABCG2,a urate exporter,by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism[J].Kidney Int,2017,91(3):658-670.DOI:10.1016/j.kint.2016.09.041. [12]CHIN K Y,NIRWANA S I,NGAH W Z.Significant association between parathyroid hormone and uric acid level in men[J].Clin Interv Aging,2015,10:1377-1380.DOI:10.2147/CIA.S90233. [13]JOHNSON R J,KANG D H,FEIG D,et al.Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?[J].Hypertension,2003,41(6):1183-1190.DOI:10.1161/01.HYP.0000069700.62727.C5. [14]KUTZING M K,FIRESTEIN B L.Altered uric acid levels and disease states[J].J Pharmacol Exp Ther,2008,324(1):1-7.DOI:10.1124/jpet.107.129031. [15]FEIG D I,KANG D H,JOHNSON R J.Uric acid and cardiovascular risk[J].N Engl J Med,2008,359(17):1811-1821.DOI:10.1056/nejmra0800885. [16]YU Z F,BRUCE-KELLER A J,GOODMAN Y,et al.Uric acid protects neurons against excitotoxic and metabolic insults in cell culture,and against focal ischemic brain injury in vivo[J].J Neurosci Res,1998,53(5):613-625.DOI:10.1002/(SICI)1097-4547(19980901)53:5<613::AID-JNR11>3.0.CO;2-1. [17]NAKAGAWA T,MAZZALI M,KANG D H,et al.Hyperuricemia causes glomerular hypertrophy in the rat[J].Am J Nephrol,2003,23(1):2-7.DOI:10.1159/000066303. [18]Kidney Disease:Improving Global Outcomes(KIDGO) CKD-MBD Work Group.KDIGO clinical practice guideline for the diagnosis,evaluation,prevention,and treatment of chronic kidney disease-mineral and bone disorder(CKD-MBD)[J].Kidney Int Suppl,2009,76(113):S1-130. [19]Erratum:Kidney Disease:Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group.KDIGO 2017 clinical practice guideline update for the diagnosis,evaluation,prevention,and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).Kidney Int Suppl.2017;7:1-59[J].Kidney Int Suppl(2011),2017,7(3):e1.DOI:10.1016/j.kisu.2017.10.001. [20]FELSENFELD A J,LEVINE B S,RODRIGUEZ M.Pathophysiology of calcium,phosphorus,and magnesium dysregulation in chronic kidney disease[J].Semin Dial,2015,28(6):564-577.DOI:10.1111/sdi.12411. [21]ANDREWS E S,PERRENOUD L,NOWAK K L,et al.Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD;a post-hoc analysis of a randomized clinical trial[J].PLoS One,2018,13(10):e0205831.DOI:10.1371/journal.pone.0205831. [22]BACCHETTA J,COCHAT P,SALUSKY I B,et al.Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function[J].Pediatr Nephrol,2012,27(7):1131-1138.DOI:10.1007/s00467-012-2110-3. [23]SAKOH T,NAKAYAMA M,TSUCHIHASHI T,et al.Associations of fibroblast growth factor 23 with urate metabolism in patients with chronic kidney disease[J].Metab Clin Exp,2016,65(10):1498-1507.DOI:10.1016/j.metabol.2016.07.005. [24]WANG Y,TAO Y,HYMAN M E,et al.Osteoporosis in China[J].Osteoporos Int,2009,20(10):1651-1662.DOI:10.1007/s00198-009-0925-y. [25]NICKOLAS T L,STEIN E,COHEN A,et al.Bone mass and microarchitecture in CKD patients with fracture[J].J Am Soc Nephrol,2010,21(8):1371-1380.DOI:10.1681/ASN.2009121208. [26]SRITARA C,ONGPHIPHADHANAKUL B,CHAILURKIT L, et al.Serum uric acid levels in relation to bone-related phenotypes in men and women[J].J Clin Densitom,2013,16(3):336-340.DOI:10.1016/j.jocd.2012.05.008. [27]MEHTA T,BUZKOVá P,SARNAK M J,et al.Serum urate levels and the risk of hip fractures:data from the Cardiovascular Health Study[J].Metab Clin Exp,2015,64(3):438-446.DOI:10.1016/j.metabol.2014.11.006. [28]PAIK J M,KIM S C,FESKANICH D,et al.Gout and risk of fracture in women:a prospective cohort study[J].Arthritis & Rheumatology (Hoboken,N.J.),2017,69(2):422-428.DOI:10.1002/art.39852. [29]TZENG H E,LIN C C,WANG I K,et al.Gout increases risk of fracture:a nationwide population-based cohort study[J].Medicine (Baltimore),2016,95(34):e4669.DOI:10.1097/MD.0000000000004669. [30]YAN D D,WANG J,HOU X H,et al.Association of serum uric acid levels with osteoporosis and bone turnover markers in a Chinese population[J].Acta Pharmacol Sin,2018,39(4):626-632.DOI:10.1038/aps.2017.165. [31]BYON C H,CHEN Y B.Molecular mechanisms of vascular calcification in chronic kidney disease:the Link between bone and the vasculature[J].Curr Osteoporos Rep,2015,13(4):206-215.DOI:10.1007/s11914-015-0270-3. [32]VERVLOET M,COZZOLINO M.Vascular calcification in chronic kidney disease:different bricks in the wall?[J].Kidney Int,2017,91(4):808-817.DOI:10.1016/j.kint.2016.09.024. [33]VERVLOET M G,ADEMA A Y,LARSSON T E,et al.The role of klotho on vascular calcification and endothelial function in chronic kidney disease[J].Semin Nephrol,2014,34(6):578-585.DOI:10.1016/j.semnephrol.2014.09.003. [34]COVIC A,VERVLOET M,MASSY Z A,et al.Bone and mineral disorders in chronic kidney disease:implications for cardiovascular health and ageing in the general population[J].Lancet Diabetes Endocrinol,2018,6(4):319-331.DOI:10.1016/S2213-8587(17)30310-8. [35]GAO J W,ZHANG K,CHEN J,et al.Roles of aldosterone in vascular calcification:an update[J].Eur J Pharmacol,2016,786:186-193.DOI:10.1016/j.ejphar.2016.05.030. [36]LEE C T,CHUA S,HSU C Y,et al.Biomarkers associated with vascular and valvular calcification in chronic hemodialysis patients[J].Dis Markers,2013,34(4):229-235.DOI:10.3233/DMA-130965. [37]KISS L Z,BAGYURA Z,CSOBAY-NOVáK C,et al.Serum uric acid is independently associated with coronary calcification in an asymptomatic population[J].J Cardiovasc Transl Res,2018.DOI:10.1007/s12265-018-9843-8. [38]KANG D H,PARK S K,LEE I K,et al.Uric acid-induced C-reactive protein expression:implication on cell proliferation and nitric oxide production of human vascular cells[J].J Am Soc Nephrol,2005,16(12):3553-3562.DOI:10.1681/ASN.2005050572. [39]D'MARCO L,GARCíA I,VEGA C.Uric acid,atherosclerosis and vascular calcifications in chronic kidney disease[J].Invest Clin,2012,53(1):52-59. [40]宋哲,赵阳,王宪,等.慢性肾功能衰竭继发高尿酸血症促进血管钙化[J].生理学报,2016,68(6):709-715.DOI:10.13294/j.aps.2016.0092. [41]LIU Z,CHEN T,NIU H T,et al.The establishment and characteristics of rat model of atherosclerosis induced by hyperuricemia[J].Stem Cells Int,2016,2016:1365257.DOI:10.1155/2016/1365257. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 504
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 582
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||